Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukaemia with a Consideration of Socio-economic Characteristics: A Retrospective Study from a Single Centre
ConclusionsSocio-demographics might influence the tyrosine kinase inhibitor that patients chose. Generic and branded imatinib as first-line therapy had comparable efficacy and safety in CML-CP patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Education | Gleevec | Leukemia | Lymphoma | Myeloma | Rural Health | Study | Universities & Medical Training